| Literature DB >> 28623882 |
Akihiro Sato1,2, Itaru Nakamura3, Hiroaki Fujita1,4, Ayaka Tsukimori1,4, Takehito Kobayashi1,4, Shinji Fukushima1, Takeshi Fujii2, Tetsuya Matsumoto4.
Abstract
BACKGROUND: The purpose of this study was to identify the clinical characteristics and outcomes of peripheral vascular catheter-related bloodstream infections (PVC-BSIs) and determine the risk of severe complications or death.Entities:
Keywords: Catheter-related bloodstream infection; Peripheral venous catheter-related bloodstream infection; Sepsis; Staphylococcus aureus
Mesh:
Year: 2017 PMID: 28623882 PMCID: PMC5474015 DOI: 10.1186/s12879-017-2536-0
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Comparison between patients who died within 30 days of bacteremia diagnosis and patients who survived
| Full cohort | Died within 30 days | Survived | Odds ratio | 95% CI |
| |
|---|---|---|---|---|---|---|
| Total | 62 | 8(100) | 54(100) | |||
| Gender (male) | 40 (64.5) | 6 (75.0) | 34 (63.0) | 0.512 | ||
| Age, median (years) | 69 (range; 1–92) | 76 (range; 52–86) | 69 (range; 1–92) | 0.126 | ||
| Duration from admission to bacteremia, median (days) | 17 (range; 3–142) | 33(range; 9–142) | 16(range; 3–86) | 0.089 | ||
| Duration of antibiotic therapy from diagnosis of PVC-BSI, median (days) | 16 (range; 5–100) | 17(range; 7–46) | 16(range; 3–100) | 0.737 | ||
| Time from catheter insertion to bacteremia, median (days) | 6 (range; 2–15) | 7 (range; 2–9) | 7 (range; 3–15) | 0.526 | ||
| Unknown | 26 (41.9) | 2 (25.0) | 24 (44.4) | 0.42 | 0.08–2.25 | 0.298 |
| < 3 days | 4 (11.1) | 2 (25.0) | 2 (3.7) | 8.67 | 1.03–73.25 | 0.022 |
| 4–7 days | 19 (52.8) | 1(16.7) | 18 (66.7) | 0.29 | 0.03–2.50 | 0.232 |
| > 8 days | 13 (36.1) | 3(50.0) | 10 (30.0) | 2.64 | 0.54–12.91 | 0.218 |
| Causative microorganism (including duplicate polymicrobials) | ||||||
| Gram-positive microorganisms | 47(58.0) | 7(77.8) | 40(54.8) | 2.45 | 0.28–21.72 | 0.408 |
|
| 14(17.3) | 5(62.5) | 9(16.7) | 8.33 | 1.68–41.29 |
|
| MSSA | 10(71.4) | 3(37.5) | 7(12.7) | 4.03 | 0.78–20.70 | 0.078 |
| MRSA | 4(28.6) | 2(25.0) | 2(3.7) | 8.67 | 1.03–73.25 | 0.022 |
| CNS | 21(25.9) | 2(25.0) | 16(29.6) | 0.79 | 0.14–4.35 | 0.788 |
|
| 6(7.4) | 0 | 6(11.1) | 0.44 | 0.02–8.53 | 0.576 |
|
| 6(7.4) | 0 | 6(11.1) | 0.44 | 0.02–8.53 | 0.576 |
| Gram-negative microorganisms | 30(35.8) | 2(22.2) | 28(38.4) | 0.31 | 0.06–1.67 | 0.156 |
|
| 9(11.1) | 0 | 6(11.1) | 0.44 | 0.02–8.53 | 0.576 |
|
| 5(6.2) | 1(12.5) | 4(7.4) | 1.79 | 0.17–18.35 | 0.621 |
|
| 4(4.9) | 1(12.5) | 3(5.6) | 2.43 | 0.22–26.69 | 0.455 |
|
| 4(4.9) | 0 | 4(7.4) | 0.66 | 0.03–13.40 | 0.785 |
|
| 4(4.9) | 0 | 4(7.4) | 0.66 | 0.03–13.40 | 0.785 |
|
| 3(3.7) | 0 | 3(5.6) | 0.87 | 0.04–18.29 | 0.926 |
|
| 1(1.2) | 0 | 1(1.9) | 2.10 | 0.08–55.84 | 0.651 |
|
| 5(6.2) | 0(0.0) | 5(6.8) | 0.53 | 0.03–10.48 | 0.671 |
| Polymicrobial | 16(25.8) | 1(12.5) | 15(27.8) | 0.37 | 0.04–3.28 | 0.357 |
| Underlying diseases (including duplicate) | ||||||
| Malignancy | 33 (53.2) | 4(50.0) | 26(48.1) | 1.08 | 0.24–4.76 | 0.922 |
| Hypertension | 14 (22.6) | 0 | 14 | 0.16 | 0.01–0.03 | 0.172 |
| Diabetes mellitus | 11 (17.7) | 0 | 11 | 0.22 | 0.01–4.15 | 0.274 |
| Cerebral infarction | 7 (11.3) | 2(25.0) | 5(9.3) | 3.27 | 0.52–20.69 | 0.189 |
| Orthopedic disorder | 3 (4.8) | 0 | 3 (5.6) | 0.87 | 0.04–18.29 | 0.926 |
| Department | ||||||
| Surgery | 35 (56.5) | 3(37.5) | 32(59.3) | 0.41 | 0.09–1.91 | 0.247 |
| Internal medicine | 21 (33.9) | 5(62.5) | 16(29.6) | 3.96 | 0.84–18.57 | 0.067 |
| Obstetrics and Gynecology | 5 (8.1) | 0 | 5 (9.3) | 0.53 | 0.03–10.48 | 0.672 |
| Pediatrics | 1 (1.6) | 0 | 1 (1.9) | 2.10 | 0.08–55.84 | 0.651 |
| Place of insertion | ||||||
| Arm | 48 (77.4) | 7 (87.5) | 41 (75.9) | 2.22 | 0.25–19.76 | 0.465 |
| Foot | 3 (4.8) | 1(12.5) | 2 (3.7) | 3.71 | 0.30–46.48 | 0.279 |
| Unknown | 11 (17.7) | 0 | 11 (20.4) | 0.22 | 0.01–4.15 | 0.274 |
| Complication | ||||||
| Suppurative thrombophlebitis | 18 (29.0) | 3(37.5) | 15(27.8) | 1.56 | 0.33–7.35 | 0.572 |
| Bacterial cellulitis | 3 (4.8) | 2 (25.0) | 1 (1.8) | 17.67 | 1.39–225.05 | 0.004 |
| Osteomyelitis | 2 (3.2) | 0 | 2 (3.7) | 1.24 | 0.05–28.02 | 0.894 |
Abbreviations: S. aureus, Staphylococcus aureus; MSSA, Methicillin-sensitive S. aureus; MRSA, Methicillin-resistant S. aureus; CNS, coagulase-negative Staphylococcus; P. aeruginosa, Pseudomonus aeruginosa; E. coli, Escherichia coli
Footnote: Some of the patients included in our study had multiple diseases. When we calculated the incidence of each underlying disease, we included the patients with multiple underlying diseases in all relevant calculations, so some patients were counted more than once
Clinical and epidemiological data of patients who died
| Case no. | Time from hospitalization to bacteremia (days) | Time from catheter insertion to bacteremia (days) | Time from bacteremia to death (days) | Complication | Microbiology |
|---|---|---|---|---|---|
| 1 | 44 | Unknown | 20 | Suppurative thrombophlebitis |
|
| 2 | 33 | Unknown | 12 | None | CNS |
| 3 | 13 | 2 | 10 | Cellulitis |
|
| 4 | 18 | 9 | 23 | Cellulitis | CNS |
| 5 | 9 | 3 | 5 | Suppurative thrombophlebitis |
|
| 6 | 44 | 7 | 19 | None |
|
| 7 | 42 | 8 | 14 | None |
|
| 8 | 142 | 9 | 25 | Suppurative thrombophlebitis |
|
Abbreviations: S. aureus, Staphylococcus aureus; CNS, coagulase-negative Staphylococcus; P. aeruginosa, Pseudomonus aeruginosa; K. oxytoca, Klebsiella oxytoca